Home > Company Overview

Pioneering Solutions for Calcified Arterial Disease

AVS is a medical device company focused on safely and effectively treating calcified arterial disease. Founded in 2017 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer, AVS is redefining interventional therapy for severely calcified lesions. And with our Pulse IVL™ system, we’re revolutionizing intravascular lithotripsy and transforming how physicians treat calcified arterial disease.

Meet Our Leadership Team

With extensive experience in foundational science, biomedical applications and product development, our visionary leadership team understands the processes, creativity and strategic mindset required to bring groundbreaking concepts to life.

Together, we are transforming the way care is delivered — helping patients overcome the challenges of calcified arterial disease to live more fulfilling lives.

Meet Our Team

A New Era of IVL

Discover how the unique Mechanism of Action of the Pulse IVL™ system enables improved deliverability and empowers operators to treat patients more efficiently and with fewer devices.

The AVS Story

2017

Founded by a collaborative clinical and engineering team from the University of Michigan
Developed device proof of concept

2018

Received grant support from NIH/Cleveland Clinic and University of Michigan’s Fast Forward Medical Innovation Program

2019

Completed successful animal study
Performed early cadaver study with positive results

2020

Secured funding from visionary healthcare investment firm, BioStar Capital

2021

Built first generation peripheral product
Completed cadaver studies with positive results confirmed by Dr. Renu Virmani and Dr. Aloke Finn at CVPath Institute
Named TCT Shark Tank Innovation finalist

2022

First patent granted
Successfully performed first peripheral human cases
Initiated product development for coronary indication

2023

Secured $28.8M in Series B funding round
Completed PV FIH POWER PAD I Study and presented results at TCT
Relocated corporate office to Boston’s Seaport District

2024

Received IDE approval for POWER PAD II Study
Began enrollment of POWER PAD II IDE Study at 20 U.S. sites

AVS Receives IDE Approval from FDA for Pivotal Intravascular Lithotripsy Study

Company’s trial will evaluate safety and efficacy of its Pulse IVL^™ system in patients with severely calcified peripheral arterial disease.

See Post

Keep Your Finger on the Pulse

Stay up to date on the latest announcements, press releases and more from AVS.

See More News

Press Release

AVS Enrolls First Patient in U.S. Pivotal Intravascular Lithotripsy Study

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has

AVS Partners with the Jacobs Institute to Expedite Clinical Trials for Coronary and Carotid Indications

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy

AVS Brings New Approach to Lithotripsy: Vanguards of Health Care

In a Vanguards of Health Care podcast episode, AVS CEO, Mark Toland sits down with BI analyst Matt Henriksson for an in-depth interview to

Pulse IVL with Angie Volk & Sean Gilligan of AVS

Angie Volk, VP of Business Development at AVS, and Sean Gilligan, COO at AVS, recently sat down with Kyle Kruse and Richard Meiklejohn on

AVS Receives IDE Approval from FDA for Pivotal Intravascular Lithotripsy Study

BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has

AVS Appoints Elizabeth Galle as Vice President of Clinical Affairs

BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™

Cardio Conversations: AVS Talks about Starting a Company in a Pandemic, Cracking Peripheral Plaques and More

Robert Chisena, Ph.D., our CTO and Co-Founder, recently chatted with Reed Miller on the latest edition of the Cardio Conversations, a MedTech Insight podcast, to share his thoughts on our interventional technology,

AVS’ PIVL™ System in growing PAD market; Details on Medtech’s new digital playbook

AVS Chief Operating Officer, Sean Gilligan, recently sat down with Tom Salemi on the DeviceTalks podcast to discuss AVS’ approach to intravascular lithotripsy and the

AVS Opens Global Headquarters in Boston’s Seaport District to Support Growth

BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™

Economic Downturn Can Still Spell Success for Medical Devices

Medical device makers navigating today’s economic climate have more hurdles to jump than in the post-Covid investment boom of 2021, and the tighter market

Let’s Talk.

Looking to learn more about the innovative Pulse IVL™ or about AVS?

Reach Out Today